{"id":29335,"date":"2015-12-01T12:03:02","date_gmt":"2015-12-01T12:03:02","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29335"},"modified":"2015-12-01T16:44:27","modified_gmt":"2015-12-01T16:44:27","slug":"us-indication-for-ledipasvirsofosbuvir-expanded","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29335","title":{"rendered":"US indication for ledipasvir\/sofosbuvir expanded"},"content":{"rendered":"<p><strong>Gilead press release<\/strong><\/p>\n<p><strong>On 12 November 2015 the US FDA approved an expanded indication for the fixed combination of ledipasvir\/sofosbuvir.<\/strong><\/p>\n<p>The expanded indication now includes treatment for genotype 4, 5 and 6 and for HIV\/HCV coinfection<\/p>\n<p>In addition, ledipasvir\/sofosbuvir plus ribavirin (RBV) for 12 weeks was approved as an alternate therapy to 24 weeks of ledipasvir\/sofosbuvir for treatment-experienced, genotype 1 patients with cirrhosis.<\/p>\n<p>The dual formulation is manufactured by Gilead and marketed under the brand name Harvoni.<\/p>\n<p>Reference:<\/p>\n<p>Gilead press statement. U.S. FDA approves new indications for Harvoni, Gilead&#8217;s once-daily single tablet regimen for chronic hepatitis C. (12 November 2015).<br \/>\n<a href=\"http:\/\/www.gilead.com\/news\/press-releases\">http:\/\/www.gilead.com\/news\/press-releases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead press release On 12 November 2015 the US FDA approved an expanded indication for the fixed combination of ledipasvir\/sofosbuvir. The expanded indication now includes treatment for genotype 4, 5 and 6 and for HIV\/HCV coinfection In addition, ledipasvir\/sofosbuvir plus &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-29335","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29335"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29335\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}